Can CTLA4 variants reduce T-cell inhibitory signaling and increase autoimmune susceptibility?

The CTLA4 gene encodes a critical immune checkpoint receptor that serves as a primary brake on T-cell activation, maintaining peripheral tolerance and preventing autoimmune responses. Genetic variations in this locus alter the delicate balance of immune regulation, predisposing individuals to systemic immune dysregulation.

Mechanistic explanations

• Checkpoint splicing and isoform ratios: The CTLA4 rs3087243 (CT60 G>A) single nucleotide polymorphism (SNP) is a regulatory variant located in the 3' untranslated region (3'UTR). The disease-susceptible G allele alters alternative splicing, leading to a reduced ratio of soluble CTLA-4 (sCTLA-4) to full-length membrane-bound CTLA-4 (flCTLA-4) mRNA.
• Loss of inhibitory signaling: Decreased levels of sCTLA-4 impair the competitive inhibition of CD28 signaling by reducing competition for the shared costimulatory ligands CD80 and CD86 on antigen-presenting cells. Phospho-proteomic studies confirm that carriers of this genetic variant display distinct intracellular phosphorylation cascades upon T-cell stimulation, resulting in a lower activation threshold and compromised regulatory T-cell (Treg) suppressive capacity.

Clinical implications

• Autoimmune susceptibility: This loss of T-cell inhibitory signaling is strongly linked to autoimmune pathology. Common variants like +49A/G and CT60 G>A are associated with a significantly increased risk of autoimmune thyroid diseases, including Graves' disease and Hashimoto's thyroiditis.
• Systemic immune activation: In severe cases, such as heterozygous germline CTLA-4 mutations, impaired signaling manifests as a monogenic syndrome featuring systemic lymphocytic infiltration, chronic enteropathy, and widespread multiorgan autoimmunity.

Bottom line

• Genetic variants in CTLA4 (such as rs3087243) act as regulatory rheostats that reduce T-cell inhibitory signaling, compromising regulatory T-cell function and significantly increasing susceptibility to both organ-specific and systemic autoimmune diseases.